Success Metrics

Clinical Success Rate
70.0%

Based on 14 completed trials

Completion Rate
70%(14/20)
Active Trials
0(0%)
Results Posted
100%(14 trials)
Terminated
6(27%)

Phase Distribution

Ph phase_2
2
9%
Ph phase_4
4
18%
Ph phase_3
15
68%
Ph early_phase_1
1
5%

Phase Distribution

1

Early Stage

2

Mid Stage

19

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
1(4.5%)
Phase 2Efficacy & side effects
2(9.1%)
Phase 3Large-scale testing
15(68.2%)
Phase 4Post-market surveillance
4(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.0%

14 of 20 finished

Non-Completion Rate

30.0%

6 ended early

Currently Active

0

trials recruiting

Total Trials

22

all time

Status Distribution
Completed(14)
Terminated(6)
Other(2)

Detailed Status

Completed14
Terminated6
unknown2

Development Timeline

Analytics

Development Status

Total Trials
22
Active
0
Success Rate
70.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.5%)
Phase 22 (9.1%)
Phase 315 (68.2%)
Phase 44 (18.2%)

Trials by Status

unknown29%
completed1464%
terminated627%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT04115319Phase 3

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Completed
NCT04513912Phase 3

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Completed
NCT03321526Phase 2

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Completed
NCT00868374Phase 3

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

Terminated
NCT00671853Phase 3

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

Completed
NCT00790192Phase 3

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Completed
NCT00619892Phase 4

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

Completed
NCT00789698Phase 3

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Completed
NCT00606541Early Phase 1

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

Terminated
NCT00811473Phase 3

Pediatric Bipolar Depression

Completed
NCT00746421Phase 4

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

Terminated
NCT01363310Phase 3

The Quietude Study: Quetiapine Use for Agitated Depression

Terminated
NCT00434876Phase 3

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence

Completed
NCT00600756Phase 3

Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone

Completed
NCT01672554Phase 3

Clinical Benefits of Seroquel XR in Anxiety Disorder

Unknown
NCT00681629Phase 4

Schizophrenic Patients in Integrated Care

Terminated
NCT00789854Phase 3

Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

Completed
NCT00389064Phase 3

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Completed
NCT01071135Phase 3

Quetiapine XR in Schizophrenic Patients

Terminated
NCT00872716Phase 2

Quetiapine in Specific Phobia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22